KidneyCAN is a nonprofit organization with a mission to accelerate cures for kidney cancer through education, advocacy, and research funding.
KIM-1, Blood-Based Biomarkers May Show Promise in Kidney Cancer
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Frontline Immunotherapy May Offer Best Chance to Cure Kidney Cancer
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Overcoming Immunotherapy Resistance Mechanisms in Kidney Cancer
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
Emphasizing The Need to Sustain Kidney Cancer Research Funding at KCRS 2025
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Personalized Kidney Cancer Vaccines Provide Direction to Immune Therapy
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Highlighting Beneficial Adjuvant/Neoadjuvant Strategies for Kidney Cancer
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Personalized Renal Vaccine Emerges as Encouraging Option in Phase 1 Study
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
Expanding and Advancing the Future of Renal Cell Carcinoma Treatment
Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.
Using Biopsies to Inform Response Characteristics in Kidney Cancer
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Novel Immunotherapy Trials May Drive Progress in Kidney Cancer Field
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Kidney Cancer Research Consortium Efforts May Improve Treatment Outcomes
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
Kidney Cancer Research Program May Play Pivotal Role in Advancing Care
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Collaboration and Research Funding Advancements in Kidney Cancer Advocacy
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
Highlighting Advocacy Impacts on Funding for Kidney Cancer Research
Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.